Mhairi Copland, PhD, BSc, MB, ChB, MRCP, FRCPath from the University of Glasgow, Glasgow, UK provides her highlights from the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA. Prof. Copland discusses the option of stopping TKI therapy in chronic myeloid leukemia (CML) patients with deep response to treatment. Prof. Copland hopes to see guidelines advising physicians on stopping therapy in the future, and explains the criteria for selecting patients eligible for stopping therapy and the results seen in clinical trials so far. Another ASH 2016 highlight for Prof. Copland is the introduction of generic imatinib, the use of which is becoming increasingly widespread in CML and will influence clinical practices. Last, Prof. Copland addresses the importance of better identifying and treating CML patients in blast phase.
This video has been supported by Incyte through an unrestricted educational grant.
